While fibrates are proven to lower triglyceride levels, which can serve as a biomarker for cardiovascular disease risk, several major clinical studies from the past 20 years have failed to show a benefit of fenofibrates over and above statins in further reducing heart-related events.
The post Millions are Taking a Drug that Falls Short of its Promise to Lower Risk of Heart Attack appeared first on MedCity News.
